ABOS News & Events

JCR Pharmaceuticals (JCRRF) announced that Acumen Pharmaceuticals (ABOS) exercised its exclusive option to develop, manufacture, and commercialize, on a global basis, up to two candidates for development in the treatment of Alzheimer's disease, enabled by JCR's proprietary blood-brain barrier-penetrating technology platform, J-Brain Cargo. The partnership, announced in July 2025, focuses on developing a BBB-penetrating treatment for AD that combines JCR's J-Brain Cargo with Acumen's amyloid beta oligomer-selective antibodies, which target toxic soluble AbetaOs, a key pathological driver in the onset and progression of AD. The collaborative program aims to demonstrate the feasibility of applying J-Brain Cargo in delivering sabirnetug, Acumen's targeted immunotherapy drug candidate, and other AbetaO-selective antibodies across the BBB to slow the progression of AD pathology. Earlier this year, Acumen presented non-clinical data from a mouse model of AD at the International Conference on Alzheimer's and Parkinson's Diseases and Related Neurological Disorders, which demonstrated that using AbetaO-selective antibodies with J-Brain Cargo technology increased brain exposure while preserving target engagement as demonstrated by AbetaO selectivity. Acumen plans to file an investigational new drug application for this program in mid-2027. Under the terms of the agreement, JCR will receive an option payment with Acumen's decision to exercise its exclusive option to develop, manufacture, and commercialize, on a global basis, up to two candidates from the collaboration. JCR will also be eligible to receive future milestone payments of up to $40M related to development, and up to $515M related to sales, for a total of up to $555M. In addition, JCR is entitled to receive tiered royalties based on net sales for any products that emerge from the collaboration.

Acumen announced the nomination of two development candidates in its Enhanced Brain Delivery, or EBD, program as treatments for AD. Building on preclinical data from both in vitro and in vivo studies, the company has exercised its option with JCR Pharmaceuticals as part of its previously signed agreement and will advance both candidates combining Acumen's AbetaO-selective antibody expertise and JCR's validated transferrin-receptor-targeting blood-brain barrier-penetrating technology, termed J-Brain Cargo. By selecting these two candidates, the company is expanding its optionality by nominating a bispecific antibody derived from sabirnetug as well as one based on a novel, next generation AbetaO-selective antibody with differentiated properties, known as ACU234.

Acumen files to sell 10.83M shares of common stock for holders